Development of an Immunotherapy for Breast Cancer
Development of an Immunotherapy for Breast Cancer
The Karen Louisa Foundation granted $51K to Dr Sarah young, a renowned International researcher at Otago University – for her research in developing a vaccine which kick starts the patients own immune response to attack the breast cancer for those with advanced and/or primary. It has the potential to selectively destroy only tumour tissue and generate an immunological memory for that particular cancer to prevent recurrence.
51,000
Raised for Sarah Young’s research in developing a vaccine.
BACK TO PROJECTS
The Karen Louisa Foundation granted $51K to Dr Sarah young, a renowned International researcher at Otago University – for her research in developing a vaccine which kick starts the patients own immune response to attack the breast cancer for those with advanced and/or primary. It has the potential to selectively destroy only tumour tissue and generate an immunological memory for that particular cancer to prevent recurrence.
In 2016/2017 KLF financially backed a study into the “Development of an Immunotherapy for Breast Cancer” with Dr Sarah Young and her team at Otago University. The project aims to develop a therapeutic vaccine for breast cancer. They focussed on developing virus-like particles (VLP) that deliver parts of the breast cancer specific protein mucin 1 (MUC1) as immunotherapy. This VLP breast cancer vaccine is aimed to generate a strong immune response against breast cancer cells that express the MUC1 protein on their surface, thereby activating specific immune cells that can kill these MUC1 expressing cancer cells. The team actually developed and generated the VLP and cultured the breast cancer cells used to test the vaccine.
The research continues with Dr Young receiving a large grant from NZBCF from the results of this seed project – we watch her work with pride and hope!
The amazing thing also about this project is that it crosses over into colorectal and prostate cancer as well!
In 2016/2017 KLF financially backed a study into the “Development of an Immunotherapy for Breast Cancer” with Dr Sarah Young and her team at Otago University. The project aims to develop a therapeutic vaccine for breast cancer. They focussed on developing virus-like particles (VLP) that deliver parts of the breast cancer specific protein mucin 1 (MUC1) as immunotherapy. This VLP breast cancer vaccine is aimed to generate a strong immune response against breast cancer cells that express the MUC1 protein on their surface, thereby activating specific immune cells that can kill these MUC1 expressing cancer cells. The team actually developed and generated the VLP and cultured the breast cancer cells used to test the vaccine.
The research continues with Dr Young receiving a large grant from NZBCF from the results of this seed project – we watch her work with pride and hope!
The amazing thing also about this project is that it crosses over into colorectal and prostate cancer as well!
